Trump pharmaceutical pricing agreements are voluntary Most-Favored-Nation deals in which drug makers pledge to match U.S. prices to the lowest prices paid in other developed nations. Supporters say they cut Medicaid spending and expand direct discounts, while critics point to uneven consumer prices and legal experts question authority and transparency. Most-Favored-Nation pricing means Americans would pay no more than patients in comparable wealthy countries.
President Trump directed that approach in a May 12, 2025 executive order, then sent July 31, 2025 letters to 17 makers threatening tariffs if U.S. prices stayed higher, according to the White House action summary. Pfizer signed the first deal on Sept. 30, 2025, followed by AstraZeneca on Oct. 10, 2025.
Table of Contents
- What these agreements cover
- Why supporters say they work
- Why critics say consumer savings are uneven
- What legal experts question
- What to check before you act
What these agreements cover
The first deals paired Medicaid pricing with a direct-purchase channel. Pfizer agreed to give every state Medicaid program Most-Favored-Nation prices and offer direct-to-consumer discounts through a new TrumpRx channel, according to the White House deal announcement. AstraZeneca made a similar Medicaid pledge and promised up to 80 percent direct discounts on chronic-disease drugs starting in 2026.
The administration launched TrumpRx.gov in Feb. 2026 as the direct-purchase portal. Initial offerings featured discounted brand drugs from five participants: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. Medicaid patients get the benefit through their state program, while cash buyers use the portal.
Why supporters say they work
Supporters focus on broad Medicaid reach and long-term savings. The White House said in Sept. 2026 that all 50 states plus D.C. and Puerto Rico now receive Most-Favored-Nation prices.
That expansion is the centerpiece of the administration savings claim. The projected effect is nearly 65 billion dollars in Medicaid drug savings over ten years. Supporters also cite direct discounts for people who pay cash for chronic-disease drugs through TrumpRx. For those buyers, a brand discount at the portal can be simpler than coupons or pharmacy shopping.
Why critics say consumer savings are uneven
Critics say portal prices do not consistently beat foreign prices. KFF compared 32 TrumpRx brand drugs to 11 peer nations and found 17 below the peer average but 15 above it, with 13 costing more than in every country compared, according to the KFF price analysis. That split means some buyers save while others still pay a premium.
📨 Get Free Accountability Coverage Alerts
Free · No spam · Unsubscribe anytime
Critics also point to offsetting increases on other drugs. An April Senate report found makers with Most-Favored-Nation deals raised list prices on hundreds of other medications while discounting select TrumpRx drugs. The practical risk is lower cost on one prescription paired with higher cost elsewhere.
What legal experts question
Legal experts question presidential authority to set prices through voluntary tariff threats and Medicaid deals. They also flag limited public text for independent review. Without full agreements, outside analysts cannot verify which products, prices and time periods count toward savings claims.
Transparency litigation has produced only partial disclosure. Public Citizen sued HHS and Commerce in federal court in D.C. for the Pfizer and Eli Lilly texts, later obtaining only heavily redacted copies, according to Fierce Pharma coverage of the lawsuits. Redactions leave patients, states and researchers unable to check the math behind advertised discounts.
What to check before you act
Confirm which path applies to you: state Medicaid or direct purchase through TrumpRx.gov. Medicaid enrollees should ask their plan whether a specific Pfizer, AstraZeneca, Eli Lilly, EMD Serono or Novo Nordisk product now carries a Most-Favored-Nation price.
Cash buyers should compare the portal price to their pharmacy, insurer and discount options for the same dose and quantity. Keep a record of list-price changes on your other prescriptions. If one drug drops on TrumpRx while another rises, show both receipts to your prescriber and pharmacist and ask about covered alternatives.
You Might Also Like
- Trump Pharmaceutical Pricing Agreements: Who Has Authority and Who Can Challenge It?
- How Trump Pharmaceutical Pricing Agreements Could Affect Public Trust and Government Accountability
- Trump Pharma Explained for 2026: Who It Affects, Key Evidence, and What to Do Next